|
Characteristics
|
RA
|
ReA
|
PsA
|
AS
|
CD
|
UC
|
SLE
|
pSS
|
sSS
|
SSc
|
PM/DM
|
HC
|
|---|
|
Total number of subjects
|
207
|
22
|
34
|
33
|
20
|
22
|
40
|
16
|
28
|
22
|
43
|
69
|
|
Ageb, years
|
54
|
23.5
|
46.5
|
44
|
33
|
35
|
37
|
50
|
53
|
53.5
|
41
|
38
|
|
25th percentile
|
43.5
|
13.8
|
33
|
29.5
|
25.5
|
29.3
|
31.3
|
48
|
39.3
|
43.5
|
26
|
27
|
|
75th percentile
|
63
|
33.5
|
54
|
51
|
43
|
45.8
|
52.3
|
63
|
63
|
58
|
58
|
41
|
|
Number of female/male subjects
|
159/48
|
8/14
|
15/19
|
9/24
|
6/14
|
9/13
|
34/6
|
14/2
|
24/4
|
17/5
|
31/12
|
37/32
|
|
Disease durationb, years
|
3
|
20 days
|
5
|
2
|
3
|
4
|
4
|
2
|
3
|
2
|
1
|
-
|
|
25th percentile
|
0.5
|
13 days
|
3
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
0.3
|
-
|
|
75th percentile
|
10
|
75 days
|
7
|
4
|
6
|
7
|
6
|
4
|
8
|
5
|
2
|
-
|
|
Serum FSTL1 levels, μg/l
| | | | | | | | | | | | |
|
Geometric mean
|
74.28
|
3.74
|
7.57
|
6.19
|
6.39
|
13.61
|
14.60
|
29.94
|
73.88
|
16.48
|
13.79
|
6.49
|
|
Lower 95% CI
|
60.89
|
2.73
|
4.99
|
5.03
|
5.35
|
9.71
|
10.49
|
15.76
|
45.79
|
7.81
|
9.97
|
5.89
|
|
Upper 95% CI
|
90.60
|
5.12
|
11.48
|
7.62
|
7.63
|
19.06
|
20.30
|
56.88
|
119.20
|
34.76
|
19.06
|
7.15
|
|
RSD (%)
|
129.17
|
104.58
|
134.90
|
63.33
|
39.06
|
112.35
|
115.27
|
148.22
|
117.81
|
133.00
|
186.28
|
36.71
|
|
Median
|
71.27
|
3.71
|
4.52
|
5.21
|
6.05
|
10.78
|
12.92
|
34.81
|
82.48
|
25.01
|
10.74
|
6.60
|
|
25th percentile
|
25.51
|
2.49
|
3.47
|
3.67
|
4.92
|
7.48
|
6.84
|
10.51
|
23.48
|
3.38
|
6.76
|
5.28
|
|
75th percentile
|
236.70
|
5.46
|
29.59
|
9.37
|
8.55
|
28.24
|
34.12
|
47.37
|
169.70
|
62.68
|
29.60
|
8.19
|
|
Above normal, %c
|
87.43
|
9.09
|
26.47
|
18.18
|
5
|
36.36
|
52.5
|
68.75
|
96.43
|
54.55
|
48.84
|
4.3
|
|
P versus HC
|
<0.001
|
<0.001
|
0.100
|
0.375
|
0.627
|
<0.001
|
<0.001
|
<0.001
|
<0.001
|
<0.001
|
0.018
|
-
|
|
P versus RA
|
-
|
<0.001
|
<0.001
|
<0.001
|
<0.001
|
<0.001
|
<0.001
|
0.013
|
0.937
|
<0.001
|
<0.001
|
<0.001
|
- aFSTL1, follistatin-like protein 1; 95% CI, 95% confidence interval; -, not determined; RSD, relative standard deviation; HC, healthy individuals; RA, rheumatoid arthritis; ReA, reactive arthritis; PsA, psoriatic arthritis; AS, ankylosing spondylitis; CD, Crohn's disease; UC, ulcerative colitis; SLE, systemic lupus erythematosus; pSS, primary Sjögren's syndrome; sSS, secondary Sjögren's syndrome; SSc, systemic sclerosis; PM/DM, polymyositis/dermatomyositis; bmedian; cnormal range denoted as mean + 2 SD was 12 μg/l.
